VRDN Relative Valuation - Viridian Therapeutics Inc - Alpha Spread

Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 22.5 USD 6.84% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Viridian Therapeutics Inc?
Write Note

Relative Value

The Relative Value of one VRDN stock under the Base Case scenario is 7.91 USD. Compared to the current market price of 22.5 USD, Viridian Therapeutics Inc is Overvalued by 65%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VRDN Relative Value
Base Case
7.91 USD
Overvaluation 65%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
0
vs Industry
2
Median 3Y
656.6
Median 5Y
159.6
Industry
7.7
Forward
4 986.8
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-3.1
Industry
23.9
Forward
-5.7
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-5
Industry
22.2
vs History
vs Industry
Median 3Y
-6.3
Median 5Y
-5
Industry
24
vs History
23
vs Industry
50
Median 3Y
2.4
Median 5Y
2.1
Industry
2.5
vs History
0
vs Industry
3
Median 3Y
435.6
Median 5Y
90.9
Industry
7.4
Forward
3 065.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.5
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-1.3
Industry
5.1
Forward
-4.8
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-1.3
Industry
4.7
Forward
-3.5
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-2.2
Industry
6.6
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-2.2
Industry
4.7
vs History
6
vs Industry
12
Median 3Y
37.3
Median 5Y
16.4
Industry
4.7

Multiples Across Competitors

VRDN Competitors Multiples
Viridian Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Viridian Therapeutics Inc
NASDAQ:VRDN
1.4B USD 5 025.5 -6.3 -3.5 -3.5
US
Abbvie Inc
NYSE:ABBV
341.9B USD 6.2 64.6 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
127.8B USD 9.5 29.6 25.9 28.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.3B USD 11.9 -251.7 26.8 28.1
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.7 22.4 27.9
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.4B USD 15.1 -485.3 213.7 328.9
P/E Multiple
Earnings Growth
US
Viridian Therapeutics Inc
NASDAQ:VRDN
Average P/E: 57.5
Negative Multiple: -6.3
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.6
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -251.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
36.7
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Viridian Therapeutics Inc
NASDAQ:VRDN
Average EV/EBITDA: 47.7
Negative Multiple: -3.5
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.9
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.7 N/A
AU
CSL Ltd
ASX:CSL
22.4
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -63 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
213.7
N/A
EV/EBIT Multiple
EBIT Growth
US
Viridian Therapeutics Inc
NASDAQ:VRDN
Average EV/EBIT: 69.5
Negative Multiple: -3.5
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
28.7
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
38%
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536 N/A
AU
CSL Ltd
ASX:CSL
27.9
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
328.9
N/A

See Also

Discover More
Back to Top